A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Buenos Aires, Argentinië, 1419HDN
- Forest Investigative Site 102
-
Buenos Aires, Argentinië, C1062ABF
- Forest Investigative Site 118
-
Buenos Aires, Argentinië, C1117ABE
- Forest Investigative Site 109
-
Buenos Aires, Argentinië, C1122AAJ
- Forest Investigative Site 104
-
Buenos Aires, Argentinië, C1126AAB
- Forest Investigative Site 108
-
Buenos Aires, Argentinië, C1181ACH
- Forest Investigative Site 114
-
Buenos Aires, Argentinië, C1209AAB
- Forest Investigative Site 106
-
Buenos Aires, Argentinië, C1405CNF
- Forest Investigative Site 119
-
Buenos Aires, Argentinië, C1413FWO
- Forest Investigative Site 122
-
Buenos Aires, Argentinië, C1419AHN
- Forest Investigative Site 107
-
Buenos Aires, Argentinië, C1425AGP
- Forest Investigative Site 111
-
Buenos Aires, Argentinië, C1425BPK
- Forest Investigative Site 121
-
Buenos Aires, Argentinië, C1428AQK
- Forest Investigative Site 115
-
Buenos Aires, Argentinië, C1428AQK
- Forest Investigative Site 116
-
Cordoba, Argentinië, X5000ALB
- Forest Investigative Site 112
-
Cordoba, Argentinië, X5004AOA
- Forest Investigative Site 124
-
Mendoza, Argentinië, M5500HYF
- Forest Investigative Site 110
-
Mendoza, Argentinië, M5504FMI
- Forest Investigative Site 125
-
Santa Fe, Argentinië, S3000FWO
- Forest Investigative Site 120
-
-
Buenos Aires
-
Banfield, Buenos Aires, Argentinië, B1828CKR
- Forest Investigative Site 103
-
La Plata, Buenos Aires, Argentinië, B1900AVG
- Forest Investigative Site 105
-
Lanus, Buenos Aires, Argentinië, C1824IBR
- Forest Investigative Site 123
-
-
Santa Fe
-
Rosario, Santa Fe, Argentinië, S2000DSV
- Forest Investigative Site 113
-
-
-
-
-
Antofagasta, Chili
- Forest Investigative Site 302
-
Santiago, Chili
- Forest Investigative Site 304
-
Santiago, Chili
- Forest Investigative Site 312
-
Valdivia, Chili
- Forest Investigative Site 306
-
-
Elqui
-
Coquimbo, Elqui, Chili
- Forest Investigative Site 308
-
-
Santiago
-
Las Condes, Santiago, Chili
- Forest Investigative Site 301
-
Las Condes, Santiago, Chili
- Forest Investigative Site 309
-
Providencia, Santiago, Chili
- Forest Investigative Site 303
-
Providencia, Santiago, Chili
- Forest Investigative Site 310
-
Recoleta, Santiago, Chili
- Forest Investigative Site 313
-
San Ramon, Santiago, Chili
- Forest Investigative Site 305
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Forest Investigative Site 206
-
San Luis Potosi, Mexico, 78090
- Forest Investigative Site 210
-
-
Coahuila
-
Saltillo, Coahuila, Mexico, 25000
- Forest Investigative Site 212
-
-
Federal District
-
Mexico City, Federal District, Mexico, 14000
- Forest Investigative Site 202
-
Mexico City, Federal District, Mexico, 14050
- Forest Investigative Site 207
-
-
Guanajuato
-
Leon, Guanajuato, Mexico, 37000
- Forest Investigative Site 211
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44610
- Forest Investigative Site 205
-
Zapopan, Jalisco, Mexico, 45200
- Forest Investigative Site 203
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 44610
- Forest Investigative Site 208
-
Monterrey, Nuevo Leon, Mexico, 64710
- Forest Investigative Site 204
-
-
Sinaloa
-
Culiacan, Sinaloa, Mexico, 80400
- Forest Investigative Site 213
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85004
- Forest Investigative Site 010
-
-
California
-
Costa Mesa, California, Verenigde Staten, 92626
- Forest Investigative Site 062
-
Fresno, California, Verenigde Staten, 93720
- Forest Investigative Site 050
-
San Francisco, California, Verenigde Staten, 94118
- Forest Investigative Site 024
-
Santa Ana, California, Verenigde Staten, 92705
- Forest Investigative Site 071
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80262
- Forest Investigative Site 002
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33486
- Forest Investigative Site 021
-
Boynton Beach, Florida, Verenigde Staten, 33426
- Forest Investigative Site 052
-
Delray Beach, Florida, Verenigde Staten, 33445
- Forest Investigative Site 070
-
Fort Myers, Florida, Verenigde Staten, 33912
- Forest Investigative Site 065
-
Hallandale Beach, Florida, Verenigde Staten, 33009
- Forest Investigative Site 043
-
Hallandale Beach, Florida, Verenigde Staten, 33009
- Forest Investigative Site 044
-
Miami, Florida, Verenigde Staten, 33137
- Forest Investigative Site 001
-
North Miami, Florida, Verenigde Staten, 33161
- Forest Investigative Site 034
-
Orlando, Florida, Verenigde Staten, 32806
- Forest Investigative Site 068
-
Palm Beach Gardens, Florida, Verenigde Staten, 33410
- Forest Investigative Site 038
-
Saint Petersburg, Florida, Verenigde Staten, 33709
- Forest Investigative Site 008
-
Tampa, Florida, Verenigde Staten, 33617
- Forest Investigative Site 028
-
-
Georgia
-
Snellville, Georgia, Verenigde Staten, 30078
- Forest Investigative Site 009
-
-
Illinois
-
Joliet, Illinois, Verenigde Staten, 60435
- Forest Investigative Site 069
-
-
Michigan
-
Kalamazoo, Michigan, Verenigde Staten, 49048
- Forest Investigative Site 045
-
-
Missouri
-
Saint Loius, Missouri, Verenigde Staten, 63104
- Forest Investigative Site 014
-
-
New Jersey
-
Long Branch, New Jersey, Verenigde Staten, 07742
- Forest Investigative Site 064
-
Morristown, New Jersey, Verenigde Staten, 07960
- Forest Investigative Site 011
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Forest Investigative Site 003
-
-
New York
-
Albany, New York, Verenigde Staten, 12205
- Forest Investigative Site 048
-
Buffalo, New York, Verenigde Staten, 14215
- Forest Investigative Site 006
-
White Plains, New York, Verenigde Staten, 10605
- Forest Investigative Site 004
-
-
Ohio
-
Centerville, Ohio, Verenigde Staten, 45459
- Forest Investigative Site 027
-
Toledo, Ohio, Verenigde Staten, 43623
- Forest Investigative Site 012
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Forest Investigative Site 020
-
-
Pennsylvania
-
Greensburg, Pennsylvania, Verenigde Staten, 15601
- Forest Investigative Site 032
-
Jenkintown, Pennsylvania, Verenigde Staten, 19046
- Forest Investigative Site 018
-
-
Rhode Island
-
East Providence, Rhode Island, Verenigde Staten, 02914
- Forest Investigative Site 067
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78757
- Forest Investigative Site 041
-
San Antonio, Texas, Verenigde Staten, 78229
- Forest Investigative Site 017
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23229
- Forest Investigative Site 013
-
-
Washington
-
Tacoma, Washington, Verenigde Staten, 98405
- Forest Investigative Site 026
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Ambulatory patients aged >/= 50 years
- Diagnostic evidence of probable Alzheimer's disease consistent with criteria from the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
- Confirmatory magnetic resonance imaging (MRI) or computed tomographic (CT) scan within the prior 12 months.
- Mini-Mental State Examination (MMSE) scores >/= 3 and </= 14 at Screening (Visit 1) and Baseline (Visit 2)
- Ongoing daily acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for at least 3 months prior to Screening (Visit 1). It is preferred that patients continue to receive the same AChEI therapy for the duration of the study.
Exclusion Criteria:
- Patients with a modified Hachinski Ischemia Score greater than 4 at Screening.
- Patients who have taken memantine within one month of Screening (Visit 1)
- Patients who have a known hypersensitivity to memantine, neramexane, rimantadine, or amantadine.
- Patients whose AChEI therapy is likely to be interrupted or discontinued during the course of the study.
- Patients who are receiving therapy with more than one AChEI.
- Patients with computed tomography (CT) or magnetic resonance imaging (MRI) evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection, or any clinically significant central nervous system disease other than Alzheimer's disease.
- Patients with a DSM-IV Axis I disorder other than Alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder.
- Patients who, in the clinician's judgement, are likely to be placed in a nursing home within the next 6 months.
- Patients who had evidence of other neurological disorders that included, but were not limited to, stroke, Parkinson's disease, seizure disorder, or head injury with loss of consciousness within the prior 5 years
- Patients who had dementia that was complicated by other organic disease
- Patients who had dementia complicated by the presence of predominant delusions
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
Oral administration, once daily.
|
Matching placebo oral administration once daily.
|
|
Actieve vergelijker: Memantine ER
28mg, once daily.
Oral administration for 24 weeks.
|
28mg(7mg capsules) once daily and oral administration for 24 weeks.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in Severe Impairment Battery (SIB) at Week 24 (LOCF)
Tijdsspanne: Baseline to week 24
|
The SIB was developed for the evaluation of cognitive function in patients with more advanced dementia, and evaluates the areas of memory, language, praxis, orientation, and attention.
The SIB test items consist of simple, one-step commands presented with gestural cues that are repeated if necessary.
The test contains 51 items, and the range of possible scores is 0 to 100 (with 0 being the worst result).
The SIB has been shown to be a valid and reliable instrument sensitive to longitudinal change.
|
Baseline to week 24
|
|
Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus) at Week 24 (LOCF)
Tijdsspanne: Week 24
|
The CIBIC-Plus is a measure of an overall clinical effect and is based on a comprehensive evaluation at Baseline and later visits of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral.
A skilled clinician interviews the patient, and includes information supplied by a knowledgeable caregiver.
The CIBIC-Plus is a rating of the patient's global status relative to Baseline, ranging from a score of 1, indicating "marked improvement" to a score of 4, indicating "no change" to a score of 7, indicating "marked worsening."
|
Week 24
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in the 19-Item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) Scale at Week 24 (LOCF)
Tijdsspanne: Baseline to week 24
|
The ADCS-ADL19 modified inventory consists of 19 items used to measure the functional capabilities of patients with moderate to severe dementia.
Each activity-of-daily-living (ADL) item comprises a series of hierarchical subquestions ranging from the highest level of independent performance to complete loss of ability to perform the ADL Inventory.
The inventory is performed by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks.
Response range is 0 (total disability) to 54 (total independence).
|
Baseline to week 24
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Stephen M Graham, PhD, Forest Laboratories
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neurocognitieve stoornissen
- Neurodegeneratieve ziekten
- Tauopathieën
- Dementie
- Ziekte van Alzheimer
- Fysiologische effecten van medicijnen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Excitatoire aminozuurantagonisten
- Opwindende aminozuurmiddelen
- Dopamine-agenten
- Antiparkinson-agenten
- Middelen tegen dyskinesie
- Memantine
Andere studie-ID-nummers
Andere studie-ID-nummers
- MEM-MD-50
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .